细胞凋亡检测市场 - 全球产业规模、份额、趋势、机会及预测（按产品、检测技术、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球细胞凋亡检测市场预计将从 2025 年的 55.7 亿美元成长到 2031 年的 80.2 亿美元，复合年增长率为 6.26%。

细胞凋亡检测是一种分析方法，用于识别和量化程序性细胞死亡，是药物研发和生物学研究中不可或缺的工具。推动该市场发展的主要因素是药物研发活动的日益活跃以及对慢性病创新治疗方法的需求不断增长。欧洲製药工业协会联合会 (EFPIA) 报告称，到 2024 年，欧洲製药业将在研发方面投入约 550 亿欧元。这项巨额投资不仅支持了药物研发管线，也推动了对精确细胞分析方法的需求，从而促进了这些检测技术的持续应用。

然而，检测设备和专用试剂的高昂营运成本阻碍了市场发展。这些资金限制往往使得预算有限的小规模研究机构难以获得高通量筛检技术。此外，执行这些检测所需的技术复杂性很高，需要熟练的专业人员，这在资源匮乏地区构成了准入障碍。因此，购买和维护这些复杂系统所需的大量资本投入构成了一项重大挑战，可能会阻碍整体市场成长。

市场驱动因素

全球癌症和慢性疾病发生率的不断上升是推动全球细胞凋亡检测市场发展的主要因素。随着恶性肿瘤发生率的上升，研究人员致力于阐明疾病进展核心的细胞死亡机制。细胞凋亡检测在此背景下至关重要，因为它能够根据化合物诱导程序性细胞死亡的能力筛检。世界卫生组织（WHO）国际癌症研究机构（IARC）于2024年2月发布题为《全球癌症负担日益加重》的新闻稿，预测到2050年，新增癌症病例将超过3500万例。这项需求的激增使得可靠的药物检验变得至关重要，不仅维持了对精准检测试剂盒的需求，也推动了公共资金的投入。美国国家癌症研究所（NCI）报告称，2024年获得了72.2亿美元的癌症研究经费，这进一步扩大了此类分析工具的应用范围。

生物製药研发投入的不断增加，透过重振药物研发管线，进一步推动了市场成长。製药公司正优先进行早期毒性筛检，利用细胞凋亡检测来识别细胞毒性风险并检验疗效。这种严格的测试对于降低后续临床试验阶段的失败率至关重要。这项工作的规模十分庞大。根据默克公司于2024年3月发布的2023年度报告，该公司研发支出高达305亿美元。如此巨额的资本投入确保了对高通量细胞凋亡筛检技术的稳定需求，从而直接推动了市场成长。

市场挑战

与检测设备和专用试剂相关的高昂营运成本是全球细胞凋亡检测市场扩张的一大障碍。小规模研究机构和学术机构通常预算有限，因此实施高通量筛检技术在经济上难以负担。这种准入限制阻碍了精准细胞分析方法的广泛应用，尤其是在资源匮乏的地区，缩小了先进检测系统的潜在基本客群。

此外，部署和维护这些高灵敏度系统所需的大量资本投入，给製药和生物技术公司带来了日益沉重的财务负担。随着产业面临优化研发成本的压力，先进细胞凋亡检测工具的高昂价格构成了一大障碍。根据国际药品製造商协会联合会（IFPMA）估计，到2024年，新药研发的平均成本将达到26亿美元。如此巨大的财务负担迫使各机构严格审查实验室支出，往往导致设备升级被推迟或继续使用价格较低廉的旧技术，从而直接阻碍了整体市场成长。

市场趋势

人工智慧 (AI) 和机器学习在数据分析中的应用，透过自动化细胞死亡标记的定量分析，正在从根本上改变全球细胞凋亡检测市场。先进的演算法正被用于处理来自高内涵筛检的大量资料集，显着降低了人工影像分析的主观性，并有助于识别细微的细胞凋亡模式。产业对数位转型的投入体现在重大的基础设施计划中。根据罗氏公司于 2025 年 4 月发布的题为「罗氏将在美国投资 500 亿美元用于製药和诊断」的新闻稿，该公司宣布计划在马萨诸塞州新建一座专注于人工智慧研究的研发中心。此类投资凸显了计算工具在检验细胞凋亡诱导化合物方面的重要作用。

3D细胞培养模型在细胞凋亡研究中的日益普及，标誌着调查方法的演进，它超越了单层培养技术，更接近地模拟了体内生理条件。球状体和类器官能够提供精确的组织结构，这对于在临床前研究中可靠地预测癌细胞对凋亡诱导剂的反应至关重要。这一转变得益于复杂模型标准化工作的推进。根据美国国立卫生研究院（NIH）2025年9月发布的题为“NIH建立全国首个专门的类器官开发中心”的新闻稿，该机构已授予一项总额达8700万美元的合同，用于启动一个标准化的类器官建模中心。这项资金表明，人们越来越依赖3D系统来增强细胞凋亡数据的临床应用价值。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球细胞凋亡检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（检测试剂盒、试剂、仪器、微孔盘）
  • 透过检测技术（光强度、流式细胞技术、细胞成像和分析系统等）
  • 依应用领域（干细胞研究、临床/诊断应用、药物发现/开发、其他）
  • 按最终用户划分（製药和生物技术公司、医院和研究机构、学术和研究机构）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美细胞凋亡检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲细胞凋亡检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区细胞凋亡检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲细胞凋亡检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲细胞凋亡检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球细胞凋亡检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc
• Merck KGaA
• Bio-Rad Laboratories Inc
• GE Healthcare Inc
• Becton Dickinson & Company
• Sartorius AG
• Genecopoeia Inc
• BioTek Instruments Inc
• Bio-Techne Corporation
• PerkinElmer Health Sciences Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Apoptosis Assays Market is projected to expand from USD 5.57 Billion in 2025 to USD 8.02 Billion by 2031, reflecting a CAGR of 6.26%. Apoptosis assays are analytical procedures designed to identify and quantify programmed cell death, serving as essential instruments in drug discovery and biological research. The market is primarily driven by intensified pharmaceutical research initiatives and the escalating demand for innovative therapeutics to manage chronic diseases. As reported by the European Federation of Pharmaceutical Industries and Associations, the pharmaceutical sector invested approximately €55,000 million in R&D within Europe in 2024. This strong financial dedication to discovery pipelines fuels the need for accurate cellular analysis methods, thereby sustaining the ongoing adoption of these detection technologies.

However, market progress is hindered by the steep operational expenses linked to assay instrumentation and specialized reagents. These financial limitations often restrict access to high-throughput screening technologies for smaller research laboratories operating with tight budgets. Additionally, the technical complexity required to execute these assays demands skilled personnel, establishing a barrier to entry in regions with fewer resources. Consequently, the significant capital investment needed to purchase and maintain these delicate systems constitutes a major challenge that could impede broader market growth.

Market Driver

The rising global incidence of cancer and chronic diseases serves as a primary catalyst for the Global Apoptosis Assays Market. As malignancy rates increase, researchers are concentrating on understanding cell death mechanisms that are central to disease progression. Apoptosis assays are indispensable in this context, allowing for the screening of compounds based on their ability to trigger programmed cell death. According to the World Health Organization's International Agency for Research on Cancer (IARC) press release 'Global cancer burden growing' from February 2024, over 35 million new cancer cases are projected by 2050. This surge necessitates robust drug validation, maintaining demand for precise detection kits, while public funding expands; the National Cancer Institute reported receiving $7.22 billion in 2024 to support cancer research, broadening the user base for these analytical tools.

Increasing investments in biopharmaceutical research and development further propel market momentum by energizing drug discovery pipelines. Pharmaceutical entities are prioritizing early-stage toxicology screening, using apoptosis assays to identify cytotoxic risks and validate efficacy. This rigorous testing is essential for reducing failure rates in subsequent clinical stages. The scale of this commitment is substantial; according to Merck & Co.'s '2023 Annual Report' from March 2024, the company's R&D expenses reached $30.5 billion. Such significant capital infusion ensures a steady consumption of high-throughput apoptosis screening technologies, directly reinforcing market growth.

Market Challenge

The substantial operational costs associated with assay instrumentation and specialized reagents present a significant barrier to the expansion of the Global Apoptosis Assays Market. Smaller research laboratories and academic institutions often operate under limited budgets, making the acquisition of high-throughput screening technologies financially impractical. This lack of accessibility restricts the widespread adoption of precise cellular analysis methods, particularly in resource-constrained regions, effectively reducing the potential customer base for advanced detection systems.

Moreover, the considerable capital investment required for acquiring and maintaining these sensitive systems exacerbates the financial strain on pharmaceutical and biotechnology firms. As the industry faces mounting pressure to optimize research expenditures, the high price of sophisticated apoptosis detection tools becomes a critical deterrent. According to the International Federation of Pharmaceutical Manufacturers and Associations, the average cost to develop a new medicine in 2024 was estimated at USD 2.6 billion. This immense financial burden compels organizations to scrutinize laboratory spending strictly, often leading to deferred equipment upgrades or the continued use of less expensive, traditional techniques, thereby directly impeding broader market growth.

Market Trends

The integration of Artificial Intelligence and Machine Learning in data analysis is fundamentally reshaping the Global Apoptosis Assays Market by automating the quantification of cell death markers. Advanced algorithms are now utilized to process massive datasets from high-content screening, significantly reducing the subjectivity associated with manual image analysis and facilitating the identification of subtle apoptotic patterns. The industry's commitment to this digital transformation is evident in major infrastructure projects; according to a Roche press release in April 2025 titled 'Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States', the company announced plans to build a new R&D center in Massachusetts dedicated to artificial intelligence research. Such investments highlight the critical role of computational tools in validating apoptosis-inducing compounds.

The rising utilization of 3D Cell Culture Models for apoptosis studies represents a methodological evolution, moving beyond monolayer techniques to better mimic in vivo physiological conditions. Spheroids and organoids provide accurate tissue architecture, which is essential for reliably predicting how cancer cells respond to apoptotic agents during preclinical testing. This transition is supported by initiatives to standardize these complex models; according to the National Institutes of Health's September 2025 press release 'NIH establishes nation's first dedicated organoid development center', the agency awarded contracts totaling $87 million to launch the Standardized Organoid Modeling Center. This funding highlights the growing reliance on three-dimensional systems to improve the translatability of apoptosis data.

Key Market Players

• Thermo Fisher Scientific Inc
• Merck KGaA
• Bio-Rad Laboratories Inc
• GE Healthcare Inc
• Becton Dickinson & Company
• Sartorius AG
• Genecopoeia Inc
• BioTek Instruments Inc
• Bio-Techne Corporation
• PerkinElmer Health Sciences Inc.

Report Scope

In this report, the Global Apoptosis Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Apoptosis Assays Market, By Product

• Assay Kits
• Reagents
• Instruments
• Microplates

Apoptosis Assays Market, By Detection Technology

• Spectrophotometry
• Flow Cytometry
• Cell Imaging and Analysis Systems
• Others

Apoptosis Assays Market, By Application

• Stem Cell Research
• Clinical and Diagnostics Application
• Drug Discovery and Development
• Others

Apoptosis Assays Market, By End User

• Pharmaceutical and Biotechnology Companies
• Hospital and Laboratories
• Academic
• Research Institutes

Apoptosis Assays Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Apoptosis Assays Market.

Available Customizations:

Global Apoptosis Assays Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Apoptosis Assays Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Assay Kits, Reagents, Instruments, Microplates)
  • 5.2.2. By Detection Technology (Spectrophotometry, Flow Cytometry, Cell Imaging and Analysis Systems, Others)
  • 5.2.3. By Application (Stem Cell Research, Clinical and Diagnostics Application, Drug Discovery and Development, Others)
  • 5.2.4. By End User (Pharmaceutical and Biotechnology Companies, Hospital and Laboratories, Academic, Research Institutes)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Apoptosis Assays Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Detection Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Apoptosis Assays Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Detection Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Apoptosis Assays Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Detection Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Apoptosis Assays Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Detection Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Apoptosis Assays Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Detection Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Apoptosis Assays Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Detection Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Apoptosis Assays Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Detection Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Apoptosis Assays Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Detection Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Apoptosis Assays Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Detection Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Apoptosis Assays Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Detection Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Apoptosis Assays Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Detection Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Apoptosis Assays Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Detection Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Apoptosis Assays Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Detection Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Apoptosis Assays Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Detection Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Apoptosis Assays Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Detection Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Apoptosis Assays Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Detection Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Apoptosis Assays Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Detection Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Apoptosis Assays Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Detection Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Apoptosis Assays Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Detection Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Apoptosis Assays Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Detection Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Apoptosis Assays Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Detection Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Apoptosis Assays Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Detection Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Apoptosis Assays Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Detection Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Apoptosis Assays Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Detection Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Apoptosis Assays Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Bio-Rad Laboratories Inc
• 15.4. GE Healthcare Inc
• 15.5. Becton Dickinson & Company
• 15.6. Sartorius AG
• 15.7. Genecopoeia Inc
• 15.8. BioTek Instruments Inc
• 15.9. Bio-Techne Corporation
• 15.10. PerkinElmer Health Sciences Inc.

16. Strategic Recommendations

17. About Us & Disclaimer